Literature DB >> 23522828

Patient experiences of having a neuroendocrine tumour: a qualitative study.

Y Feinberg1, C Law, S Singh, F C Wright.   

Abstract

BACKGROUND AND OBJECTIVES: Limited qualitative studies exist regarding the patient experience of having a rare cancer. We sought to understand the patient experience of having a rare malignancy by interviewing patients diagnosed with neuroendocrine tumours (NET).
METHODS: Semi-structured qualitative interviews were used to examine the cancer journey experience of NET patients. Purposive sampling was utilized and 18 telephone interviews were completed by a single interviewer. Eight interviewees were female, median age was 63 (age range 45-77). Median interview time was 31 min (range 9 min - 2 h 8 min). Patient interviews were transcribed verbatim and analysed using qualitative research methodology. Grounded theory guided the generation of the interview guide and analysis.
RESULTS: The dominant theme identified was that of 'no clear pathway' of care for the patient with NETs. Four subthemes that influenced this theory included: (1) difficulty with obtaining a diagnosis; (2) difficulty finding appropriate information about NETs from physicians; (3) difficulty finding treatment centres with knowledge of NETs and (4) difficulty finding disease specific support. Two global modifiers were also identified; satisfaction with a specialized clinic and long term physical and psychological side effects of treatment. These modifiers did not affect the overall theme but do potentially offer a solution for some of the difficulties the patients experienced.
CONCLUSIONS: Patients with NETs had 'no clear pathway' of care in their cancer journey. A multidisciplinary specialized clinic for NETs is recommended as well as a strong role for nursing in providing support and building patient and family resilience.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Multidisciplinary clinic; Neuroendocrine tumours; Patient care pathway; Patient experience; Qualitative research; Rare diseases; Social support

Mesh:

Year:  2013        PMID: 23522828     DOI: 10.1016/j.ejon.2013.02.003

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  14 in total

1.  Operationalizing patient-centered cancer care: A systematic review and synthesis of the qualitative literature on cancer patients' needs, values, and preferences.

Authors:  Kerri-Anne R Mitchell; Kelly J Brassil; Serena A Rodriguez; Edward Tsai; Kayo Fujimoto; Kate J Krause; L Aubree Shay; Andrew E Springer
Journal:  Psychooncology       Date:  2020-08-23       Impact factor: 3.894

2.  Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours.

Authors:  Vanessa L Beesley; Matthew Burge; Monica Dumbrava; Jack Callum; Rachel E Neale; David K Wyld
Journal:  Support Care Cancer       Date:  2018-03-29       Impact factor: 3.603

3.  Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter?

Authors:  J Hallet; N G Coburn; S Singh; K Beyfuss; S Koujanian; N Liu; C H L Law
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

4.  Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes.

Authors:  Julie Hallet; Laura E Davis; Alyson L Mahar; Calvin H L Law; Elie Isenberg-Grzeda; Lev D Bubis; Simron Singh; Sten Myrehaug; Haoyu Zhao; Kaitlyn Beyfuss; Lesley Moody; Natalie G Coburn
Journal:  Oncologist       Date:  2019-07-03

5.  Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.

Authors:  Simron Singh; Dan Granberg; Edward Wolin; Richard Warner; Maia Sissons; Teodora Kolarova; Grace Goldstein; Marianne Pavel; Kjell Öberg; John Leyden
Journal:  J Glob Oncol       Date:  2016-06-08

6.  Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States.

Authors:  Edward M Wolin; John Leyden; Grace Goldstein; Teodora Kolarova; Ron Hollander; Richard R P Warner
Journal:  Pancreas       Date:  2017 May/Jun       Impact factor: 3.327

7.  Delays and routes to diagnosis of neuroendocrine tumours.

Authors:  Ron Basuroy; Catherine Bouvier; John Keith Ramage; Maia Sissons; Raj Srirajaskanthan
Journal:  BMC Cancer       Date:  2018-11-16       Impact factor: 4.430

8.  Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial.

Authors:  L D de Hosson; G Bouma; J Stelwagen; H van Essen; G H de Bock; D J A de Groot; E G E de Vries; A M E Walenkamp
Journal:  Orphanet J Rare Dis       Date:  2019-02-28       Impact factor: 4.123

9.  Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey.

Authors:  Eline de Heus; Vivian Engelen; Irene Dingemans; Carol Richel; Marga Schrieks; Jan Maarten van der Zwan; Marc G Besselink; Mark I van Berge Henegouwen; Carla M L van Herpen; Saskia F A Duijts
Journal:  Orphanet J Rare Dis       Date:  2021-06-01       Impact factor: 4.123

10.  Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study.

Authors:  Jordan Sibeoni; Wafaa Khannoussi; Emilie Manolios; Vinciane Rebours; Anne Revah-Levy; Philippe Ruszniewski
Journal:  Oncotarget       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.